1223498-69-8|BAY-1000394, developed by Bayer, inhibits CDKs involved in the cell cycle (CDK1, CDK2, CDK3 and CDK4) along with the one implicated in the regulation of transcription (CDK7 and CDK9), with IC50 values ranging from 5 to 25 nM. This compound is in phase I clinical development for various types of tumours. BAY-1000394 studies also shown that it could be efficient in combination with cisplatin . BAY 1000394 clearly overcomes many limitations of other drugs since it displays high solubility in water, even at neutral pH, and low efficacious oral doses. Furthermore, BAY 1000394 has proven antitumor activity in xenograft models resistant to standard drugs such as doxorubicin, cisplatin, or paclitaxel, and has shown its potential for combination treatment with drugs on the market . The full story about this nanomolar pan-CDK inhibitor BAY 1000394, which contains an unusual sulfoximide group, has been recently disclosed.
Copyright © 2014-2015 Tubepharm. All Rights Reserved.
Tel：+86 021 5433 8626 Fax：+86 021 5433 8626*801 E-mail: email@example.com
All of our products, unless clearly indicated otherwise, are sold for research or manufacturing purposes only, are not for human, veterinary and household use.
The products under valid patent protection are not offered at this time. It is fully client's responsibility to comply with the rules, regulations and patent laws.